pediatric acute myeloid leukemia

ANOTHER FIRST: FDA APPROVES CAR T-IMMUNOTHERAPY FOR TREATMENT OF AGGRESSIVE FORM OF INDOLENT NON-HODGKIN LYMPHOMA By Lee Greenberger, PhD, Chief Scientific Officer at LLS | March, 2021 The U.S. Food and Drug Administration (FDA) today approved the CAR T-cell treatment axicabtagene…